Search results
Showing 31 to 45 of 64 results for hepatocellular carcinoma
Awaiting development [GID-TA11008] Expected publication date: TBC
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
Awaiting development [GID-TA11019] Expected publication date: TBC
Awaiting development [GID-TA10911] Expected publication date: TBC
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
Ex-vivo hepatic resection and reimplantation for liver cancer (IPG298)
Evidence-based recommendations on ex-vivo hepatic resection and reimplantation for liver cancer. This involves removing the liver from the body, cutting away the diseased tissue, and reimplanting the remaining tumour-free liver into the patient.
View recommendations for IPG298Show all sections
Sections for IPG298
Hearing impairment - cochlear implants 26 November 2008 TA189 Hepatocellular carcinoma (advanced and metastatic)- sorafenib 26 February...
Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for IPG788Show all sections
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued [GID-TA10221]
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued [GID-TA10380]
Awaiting development [GID-TA11538] Expected publication date: TBC
Awaiting development [GID-TA11653] Expected publication date: TBC
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued [GID-TA10830]
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)